Pearlman Richard, Hanna Renee, Burmeister Jay, Abrams Judith, Dominello Michael
Detroit Medical Center, Detroit, Michigan.
Michigan State University College of Human Medicine, Lansing, Michigan.
Adv Radiat Oncol. 2021 May 19;6(4):100723. doi: 10.1016/j.adro.2021.100723. eCollection 2021 Jul-Aug.
Several adverse effects have been reported in the literature associated with total body irradiation (TBI). Reports of the adverse effects of TBI have been primarily drawn from single-institution retrospective analyses. We report, to our knowledge, one of the largest cohorts of patients treated with TBI using multiple preparative chemotherapy and radiation regimens.
A retrospective chart review was performed for all 705 patients treated with TBI at our institution from 1995 to 2017. Based on availability of TBI records, 622 patients (88%) had sufficient evaluable documentation for analysis. Patients received 1 of 4 conditioning regimens: busulfan-fludarabine, 2 Gy (BUFLU); fludarabine-melphalan, 2 Gy (FLUMEL); cyclophosphamide, 12 Gy fractionated (CY); or etoposide, 12 Gy fractionated (VP16). Individual patients were evaluated for 13 specific recognized adverse effects based on the Common Terminology Criteria for Adverse Events, version 5.0.
Mucositis (grade 3) was the most common serious adverse effect and occurred most frequently in the group receiving the VP16 12 Gy regimen (40% vs less than 14% in each of the other groups). Serious febrile neutropenia (grade 3-5) was less frequent (24%) among patients receiving CY than among those receiving the other conditioning regimens (more than 38% in each of the other groups). The incidence of serious lung infection was less common (5%) in patients receiving CY than in those receiving VP16 (18%). There was a higher frequency of grade 3-5 diarrhea among those receiving FLUMEL (5%) and VP16 (4%) than in the other groups (<3%) ( = .034). Otherwise, there were no detectable differences in serious toxicity by regimen for the 13 adverse effects reviewed. Only 2 secondary malignancies were reported, and both were in the BUFLU group. Cataract formation occurred in approximately 16% of patients overall, and the rates were similar across regimens. Median time to cataract formation was 1 to 4 years across regimens, with cataracts occurring earlier in the 2-Gy regimens. The overall rate of grade ≥3 pneumonitis was approximately 2% across the entire cohort.
Our nearly 20-year TBI experience showed relatively low rates of radiation-related toxicities. However, cataracts were common with a relatively short onset time.
文献中已报道了与全身照射(TBI)相关的几种不良反应。TBI不良反应的报告主要来自单机构回顾性分析。据我们所知,我们报告了接受TBI治疗的最大患者队列之一,采用了多种预处理化疗和放疗方案。
对1995年至2017年在我们机构接受TBI治疗的所有705例患者进行回顾性病历审查。根据TBI记录的可用性,622例患者(88%)有足够的可评估文件用于分析。患者接受4种预处理方案中的1种:白消安-氟达拉滨,2 Gy(BUFLU);氟达拉滨-美法仑,2 Gy(FLUMEL);环磷酰胺,12 Gy分次照射(CY);或依托泊苷,12 Gy分次照射(VP16)。根据不良事件通用术语标准第5.0版,对个体患者评估13种特定的公认不良反应。
黏膜炎(3级)是最常见的严重不良反应,在接受VP16 12 Gy方案的组中发生频率最高(40%,而其他组均低于14%)。接受CY的患者中严重发热性中性粒细胞减少(3 - 5级)的频率(24%)低于接受其他预处理方案的患者(其他组均超过38%)。接受CY的患者中严重肺部感染的发生率(5%)低于接受VP16的患者(18%)。接受FLUMEL(5%)和VP16(4%)的患者中3 - 5级腹泻的频率高于其他组(<3%)(P = 0.034)。否则,在所审查的13种不良反应中,各方案在严重毒性方面未发现可检测到的差异。仅报告了2例继发性恶性肿瘤,均在BUFLU组。总体约16%的患者发生白内障,各方案发生率相似。各方案白内障形成的中位时间为1至4年,2 Gy方案中白内障出现更早。整个队列中≥3级肺炎的总体发生率约为2%。
我们近20年的TBI经验显示辐射相关毒性发生率相对较低。然而,白内障很常见,发病时间相对较短。